Volume 14, Number 1—January 2008
THEME ISSUE
International Polar Year
Research
International Circumpolar Surveillance System for Invasive Pneumococcal Disease, 1999–2005
Table 8
Factor or condition | Alaska, 1999–2005, no. (%) | Northern Canada, 1999–2005, no. (%) |
---|---|---|
Cigarette smoking | 223 (44) | 54 (40) |
Alcohol abuse† | 201 (39) | 50 (37) |
Chronic lung disease/asthma | 139 (27) | 26 (19) |
Diabetes mellitus | 71 (14) | 22 (16) |
Immunosuppressive therapy | 35 (7) | 5 (4) |
Injection drug use | 11 (2) | 3 (2) |
Asplenia | 9 (2) | 4 (3) |
Total | 509 (100) | 135 (100) |
*Risk factors and medical conditions are not mutually exclusive. Each case may have >1 condition reported. Data were not available for Greenland, Iceland, Norway, northern Sweden, or Finland.
†Alcohol abuse was noted in the chart.
1Current affiliation: National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia
2The International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group: Jean-François Proulx (Department of Public Health, Nunavik Regional Board of Health and Social Services, Quebec City, Quebec, Canada); Robert Carlin (Department of Public Health, Cree Board of Health and Social Services of James Bay, Montreal, Quebec, Canada); Andre Corriveau, Cheryl Case (Northwest Territory Department of Health and Social Services, Yellowknife, Northwest Territories, Canada); Bryce Larke, Colleen Hemsley (Yukon Health and Social Services, Whitehorse, Yukon, Canada); Isaac Sobel, Carolina Palacios (Nunavut Department of Health, Iqaluit, Nunavut, Canada); Gregory Tyrell, Marguerite Lovgren (National Centre for Streptococcus, Edmonton, Alberta, Canada); Alisa Reasonover, Michael G. Bruce, Tammy Zulz, Dana Bruden, Thomas W. Hennessy, Alan J. Parkinson (Centers for Disease Control and Prevention, Anchorage, Alaska, USA); Shelley L. Deeks (National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia); Christine Navarro (Public Health Agency of Canada, Ottawa, Ontario, Canada); Louise Jette (Quebec Public Health Laboratory, Ste. Anne-de-Bellevue, Quebec, Canada); Karl Kristinsson, Gudrun Sigmundsdottir (Landspitali University Hospital, Reykjavik, Iceland); Knud Brinkløv Jensen (Institution of the Chief Medical Officer, Nuuk, Greenland); Oistein Lovoll (Norwegian Institute of Public Health, Oslo, Norway); J. Pekka Nuorti (National Public Health Institute, Helsinki, Finland); Elja Herva (National Public Health Institute, Oulu, Finland); Anders Sjostedt (Umea University, Umea, Sweden); Anders Nystedt (Sunderby Hospital, Lulea, Sweden); and Anders Koch (Statens Serum Institut, Copenhagen, Denmark)